Reviewing Novavax Inc. (NVAX)’s and Zosano Pharma Corporation (NASDAQ:ZSAN)’s results

Novavax Inc. (NASDAQ:NVAX) and Zosano Pharma Corporation (NASDAQ:ZSAN) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax Inc. 38.57M 21.84 186.26M -0.53 0.00
Zosano Pharma Corporation N/A 0.00 32.70M -9.39 0.00

In table 1 we can see Novavax Inc. and Zosano Pharma Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Novavax Inc. and Zosano Pharma Corporation.

Net Margins Return on Equity Return on Assets
Novavax Inc. -482.91% 179.3% -66.8%
Zosano Pharma Corporation 0.00% -185.2% -116.3%

Risk and Volatility

Novavax Inc. has a beta of 2.35 and its 135.00% more volatile than Standard and Poor’s 500. Competitively, Zosano Pharma Corporation is 82.00% more volatile than Standard and Poor’s 500, because of the 1.82 beta.

Liquidity

The current Quick Ratio of Novavax Inc. is 3.4 while its Current Ratio is 3.4. Meanwhile, Zosano Pharma Corporation has a Current Ratio of 5.4 while its Quick Ratio is 5.4. Zosano Pharma Corporation is better positioned to pay off its short-term and long-term debts than Novavax Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Novavax Inc. and Zosano Pharma Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Novavax Inc. 0 0 4 3.00
Zosano Pharma Corporation 0 0 0 0.00

Novavax Inc. has a 127.27% upside potential and a consensus price target of $5.

Insider & Institutional Ownership

Institutional investors held 42.1% of Novavax Inc. shares and 59.7% of Zosano Pharma Corporation shares. Insiders held 1.16% of Novavax Inc. shares. Competitively, insiders own roughly 1.97% of Zosano Pharma Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Novavax Inc. 3.38% 8.63% 44.59% 36.31% 51.77% 72.58%
Zosano Pharma Corporation -3.74% -9.32% -7.93% -20.18% -68.48% -65.38%

For the past year Novavax Inc. had bullish trend while Zosano Pharma Corporation had bearish trend.

Summary

Novavax Inc. beats on 7 of the 10 factors Zosano Pharma Corporation.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.